Tennessee Retina at ARVO 2026
Advancing Vision Care: Our Team’s Impact at ARVO 2026
Last week, members of our team traveled to Denver, Colorado to attend the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting—the premier global event for eye and vision research. With more than 11,000 members worldwide, ARVO brings together clinicians, scientists, and innovators who are shaping the future of ophthalmology.
We were proud to have strong representation at this year’s meeting, including Dr. Thomas, Dr. Allphin (our current fellow), Tom Murickan, and Ifrah Khurram, a medical student actively engaged in research with our team.
Contributing to Cutting-Edge Research
Our team didn’t just attend; they contributed meaningful research presentations that reflect our commitment to advancing patient care.
- Dr. Thomas presented on the DAVIO 2 Phase 2 Trial, which evaluates vision outcomes using a bioerodible intravitreal insert (EYP-1901, vorolanib) compared to aflibercept in treating wet age-related macular degeneration (wAMD). This work explores promising approaches to improving treatment durability and outcomes for patients with this chronic condition.
- Dr. Allphin shared insights on the utility of genetic testing in guiding treatment decisions for patients with suspected Stickler Syndrome. Her work highlights the growing importance of precision medicine in ophthalmology and how genetics can influence both diagnosis and long-term care strategies.
- Tom Murickan presented an important analysis on the financial impact of anti-VEGF drug durability, focusing on cost implications for both patients and the healthcare system. His research underscores the critical intersection between clinical effectiveness and economic sustainability in modern medicine.
The experience allows our team to stay at the forefront of innovation while building connections that ultimately benefit our patients and community.
Looking Ahead
We are incredibly proud of our team for their dedication to research, education, and advancing the standard of care in ophthalmology. Their participation in ARVO reflects our ongoing commitment to combining clinical excellence with meaningful scientific contributions.
We look forward to continuing this work, and to bringing the latest advancements in vision care directly to the patients we serve.
